skip to main content
Idioma:
Result Number Material Type Add to My Shelf Action Record Details and Options
1
Activity and shelter-related behavior in Rhodnius prolixus: The role of host odours
Activity and shelter-related behavior in Rhodnius prolixus: The role of host odours
Material Type:
Artigo 		Adicionar ao Meu Espaço

Activity and shelter-related behavior in Rhodnius prolixus: The role of host odours

Ferreira, R.A. ; Guarneri, A.A. ; Lorenzo, M.G.

Acta tropica, 2019-08, Vol.196, p.150-154 [Periódico revisado por pares]

Netherlands: Elsevier B.V

Texto completo disponível

Citações Citado por
2
Association of tumor-infiltrating lymphocytes with distant disease-free survival in the ShortHER randomized adjuvant trial for patients with early HER2+ breast cancer
Association of tumor-infiltrating lymphocytes with distant disease-free survival in the ShortHER randomized adjuvant trial for patients with early HER2+ breast cancer
Material Type:
Artigo 		Adicionar ao Meu Espaço

Association of tumor-infiltrating lymphocytes with distant disease-free survival in the ShortHER randomized adjuvant trial for patients with early HER2+ breast cancer

Dieci, M.V. ; Conte, P. ; Bisagni, G. ; Brandes, A.A. ; Frassoldati, A. ; Cavanna, L. ; Musolino, A. ; Giotta, F. ; Rimanti, A. ; Garrone, O. ; Bertone, E. ; Cagossi, K. ; Sarti, S. ; Ferro, A. ; Piacentini, F. ; Maiorana, A. ; Orvieto, E. ; Sanders, M. ; Miglietta, F. ; Balduzzi, S. ; D’Amico, R. ; Guarneri, V.

Annals of oncology, 2019-03, Vol.30 (3), p.418-423 [Periódico revisado por pares]

England: Elsevier Ltd

Texto completo disponível

Citações Citado por
3
Project management and analysis of investment plans in public works: optimization processes choices to maximize resource allocation results
Project management and analysis of investment plans in public works: optimization processes choices to maximize resource allocation results
Material Type:
Artigo 		Adicionar ao Meu Espaço

Project management and analysis of investment plans in public works: optimization processes choices to maximize resource allocation results

Arnao, A.A. ; Guarneri, R. ; Lo Bosco, R. ; Puglisi, A.

Applied mathematical sciences, 2023, Vol.17 (9), p.399-412

Sem texto completo

Citações Citado por
4
Validation of the American Joint Committee on Cancer new prognostic stage groups for HER2-positive breast cancer patients treated with adjuvant chemotherapy and trastuzumab in the prospective ShortHER trial
Validation of the American Joint Committee on Cancer new prognostic stage groups for HER2-positive breast cancer patients treated with adjuvant chemotherapy and trastuzumab in the prospective ShortHER trial
Material Type:
Artigo 		Adicionar ao Meu Espaço

Validation of the American Joint Committee on Cancer new prognostic stage groups for HER2-positive breast cancer patients treated with adjuvant chemotherapy and trastuzumab in the prospective ShortHER trial

Dieci, M.V. ; Bisagni, G. ; Brandes, A.A. ; Frassoldati, A. ; Donadio, M. ; Garrone, O. ; Piacentini, F. ; Balduzzi, S. ; Guarneri, V. ; Conte, P.F.

Annals of oncology, 2019-05, Vol.30, p.iii27-iii28 [Periódico revisado por pares]

England: Elsevier Ltd

Texto completo disponível

Citações Citado por
5
41O Nine weeks vs 1-year adjuvant trastuzumab: Long term outcomes of the ShortHER randomised trial
41O Nine weeks vs 1-year adjuvant trastuzumab: Long term outcomes of the ShortHER randomised trial
Material Type:
Artigo 		Adicionar ao Meu Espaço

41O Nine weeks vs 1-year adjuvant trastuzumab: Long term outcomes of the ShortHER randomised trial

Conte, P.F. ; Frassoldati, A. ; Bisagni, G. ; Brandes, A.A. ; Donadio, M. ; Garrone, O. ; Piacentini, F. ; Cavanna, L. ; Giotta, F. ; Aieta, M. ; Gebbia, V. ; Musolino, A. ; Ferro, A. ; Danese, S. ; Zamagni, C. ; Nanni, O. ; Dieci, M.V. ; Vicini, R. ; Balduzzi, S. ; Guarneri, V.

Annals of oncology, 2021-05, Vol.32, p.S37 [Periódico revisado por pares]

Texto completo disponível

Citações Citado por
6
9 weeks versus 1 year adjuvant trastuzumab for HER2+ early breast cancer: Subgroup analysis of the ShortHER trial allows to identify patients for whom a shorter trastuzumab administration may have a favourable risk/benefit ratio
9 weeks versus 1 year adjuvant trastuzumab for HER2+ early breast cancer: Subgroup analysis of the ShortHER trial allows to identify patients for whom a shorter trastuzumab administration may have a favourable risk/benefit ratio
Material Type:
Artigo 		Adicionar ao Meu Espaço

9 weeks versus 1 year adjuvant trastuzumab for HER2+ early breast cancer: Subgroup analysis of the ShortHER trial allows to identify patients for whom a shorter trastuzumab administration may have a favourable risk/benefit ratio

Conte, P.F. ; Guarneri, V. ; Bisagni, G. ; Piacentini, F. ; Brandes, A.A. ; Cavanna, L. ; Giotta, F. ; Aieta, M. ; Gebbia, V. ; Frassoldati, A. ; Musolino, A. ; Garrone, O. ; Taverniti, C. ; Rimanti, A. ; Sarti, S. ; Rubino, D. ; Bologna, A. ; Vicini, R. ; Balduzzi, S. ; D'Amico, R.

Annals of oncology, 2018-10, Vol.29, p.viii705-viii705 [Periódico revisado por pares]

England: Elsevier Ltd

Texto completo disponível

Citações Citado por
7
19P PIK3CA mutations in HER2-positive early breast cancer patients enrolled in the adjuvant randomized short-HER study
19P PIK3CA mutations in HER2-positive early breast cancer patients enrolled in the adjuvant randomized short-HER study
Material Type:
Artigo 		Adicionar ao Meu Espaço

19P PIK3CA mutations in HER2-positive early breast cancer patients enrolled in the adjuvant randomized short-HER study

Guarneri, V. ; Dieci, M.V. ; Bisagni, G. ; Brandes, A.A. ; Frassoldati, A. ; Cavanna, L. ; Musolino, A. ; Giotta, F. ; Rimanti, A. ; Garrone, O. ; Bertone, E. ; Cagossi, K. ; Nanni, O. ; Piacentini, F. ; Orvieto, E. ; Curtarello, M. ; Chic, N. ; D'Amico, R. ; Prat, A. ; Conte, P.F.

Annals of oncology, 2020-05, Vol.31, p.S23-S23 [Periódico revisado por pares]

Elsevier Ltd

Texto completo disponível

Citações Citado por
8
Tumor-infiltrating lymphocytes (TILs) as an independent prognostic factor for early HER2+ breast cancer patients treated with adjuvant chemotherapy and trastuzumab in the randomized shortHER trial
Tumor-infiltrating lymphocytes (TILs) as an independent prognostic factor for early HER2+ breast cancer patients treated with adjuvant chemotherapy and trastuzumab in the randomized shortHER trial
Material Type:
Artigo 		Adicionar ao Meu Espaço

Tumor-infiltrating lymphocytes (TILs) as an independent prognostic factor for early HER2+ breast cancer patients treated with adjuvant chemotherapy and trastuzumab in the randomized shortHER trial

Dieci, M.V. ; Conte, P.F. ; Bisagni, G. ; Brandes, A.A. ; Frassoldati, A. ; Cavanna, L. ; Musolino, A. ; Giotta, F. ; Rimanti, A. ; Garrone, O. ; Bertone, E. ; Cagossi, K. ; Sarti, S. ; Ferro, A. ; Omarini, C. ; Maiorana, A. ; Orvieto, E. ; Sanders, M. ; D'Amico, R. ; Guarneri, V.

Annals of oncology, 2018-10, Vol.29, p.viii58-viii59 [Periódico revisado por pares]

England: Elsevier Ltd

Texto completo disponível

Citações Citado por

Personalize Seus Resultados

  1. Editar

Refine Search Results

Expandir Meus Resultados

  1.   

Mostrar Somente

  1. Recursos Online (7)
  2. Revistas revisadas por pares (7)

Data de Publicação 

De até
Refinar
  1. Antes de2018  (1)
  2. 2018Até2018  (2)
  3. 2019Até2019  (3)
  4. 2020Até2021  (2)
  5. Após 2021  (1)
  6. Mais opções open sub menu

  • Realização: ABCD-USP USP   Logos de Redes Sociais: Freepik

Buscando em bases de dados remotas. Favor aguardar.